Taipei Medical University
  • 2019 Nov 18
  • International Biomed accelerator program Pitch Day cooperated with Taipei Medical University, Academia Sinica, AstraZeneca was successfully concluded

2019/10/26 NBRP Biomed Startup Challenge Pitch Day


The NBRP Biomed Startup Challenge, a collaboration between the Academia Sinica Biomedical Translation Research Center and AstraZeneca (AZ) and Taipei Medical University, this program joint AZ's global iDream program and resources from the Taipei Medical University. Particularly for the topic such as Oncology, Cardiovascular / nephrology / metabolic diseases, Respiratory diseases,Digital health, In total 31 groups of Startup teams registered from local and abroad, there are selected 16 outstanding teams through the company review and 1on1 interview and participate in the final selection on Pitch Day on October 26.
 
Among the short-listed selection teams, there are startup use the Internet of Things technology to solve the pathology tracking and management, as well as the application of digital technology and big data to improve the accuracy of physician diagnosis, and studying in the field of oncology, expecting to provide not only personalized and precise treatments and new drugs in the future, but also significantly improve anti-cancer effects through digital medicine for preventive testing and post-operative tracking.
 
In this Pitch Day competition, Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park Biomedical Translation Research Center, Justin Chin,  the President of Taiwan AstraZeneca Co., Ltd., Chen, Mei-Ling, Chairman of the National Development Council, and Lin, Chien-Huang, President of Taipei Medical University, gave speech. Numbers of important VIP guests also attended the event, including Vice President Chen, Chien-Jen, Vice President of the Ministry of Science and Technology Shieh, Dar-Bin, President of the Academia Sinica James C. Liao, AZ Global Business Development Operations Senior Vice President Shaun Grady; and Taipei Medical University Chairman Chang, Wen-Chang, National Health Research Institutes (NHRI), Liang, Kung-Yee, the representative of the British Office in Taiwan, Catherine Nettleton, and the academician of the Academia Sinica, Wang, Hui-Zhen, and others.



Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park
 
Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park, said that after 10 years of planning, the Biotech Park will is completed for about a year. With the help of AS-BioTReC, the Biotechnology Park has abundant biomedical research and development energy, and this International Biomedical Accelerator Program is one of the important strategies. This biomedical accelerator cooperation program has AZ and Taipei Medical University assisted in the selection, promotion, evaluation and course training to accelerate the development of research and results to the international.



Justin Chin, the President of Taiwan AstraZeneca Co., Ltd
 

Justin Chin, the President of Taiwan AstraZeneca Co., Ltd, said that AZ not only leads the world in new drug research and development, but also invests 25% of its revenue in innovative research, and attaches great importance to innovation science. In the past three years, AZ has introduced five drugs related to cancer, respiratory and cardiovascular diseases, and it is expected to bring better treatment to patients. In the past five years, the investment in clinical trials has exceeded NT$1.3 billion. In the past three years, the clinical scale has ranked first in Taiwan. Among the global biomedical research and development programs iDREAM launched by AZ, Taiwan is the fifth country to join the establishment. AZ will spare our best effort to become the international coaching energy of the winning team, and jointly promote the integration of biomedical research and development.



Lin, Chien-Huang, President of Taipei Medical University
 
Taipei Medical University plays a pivotal role in clinical research and study. President Lin, Chien-Huang of Taipei Medical University said: The medical system of the Seventh Hospital of Taipei Medical University has a wealth of clinical and innovative resources, providing teams to conduct a one-stop commercial guidance for complete medical treatment. In the short term, the product results and company value will be greatly improved, and through the Taipei Medical University Accelerator, for market trends, regulatory strategies, clinical evaluation, IT integration and other examples, as well as one-on-one consultation with medical consultants, clinical database resources, international resources. Linking, accelerating team product development and entering the market. It has successfully coached many local and foreign biomedical startups to conduct industry and university cooperation and enter to the clinical market. After the establishment of the biomedical industrial park in the future Shuanghe Hospital Campus, it will become an important base to further promote the success of the startup company. At present, the Taipei Medical University Accelerator has cooperated closely with internationally renowned university accelerators such as Stanford Biodesign, UCSF QB3, StartX, and internationally renowned entrepreneurial accelerators such as 500 Startups. It also recruits newcomers with the flank accelerator and the US MassChallenge team.




Chen, Mei-Ling, Chairman of the National Development Council
 
Chen, Mei-Ling, Chairman of the National Development Council pointed out that Taiwan's medical system has rich clinical trial energy and first-class medical professionals which has won world recognition. In 2019, the World Economic Forum ranked Taiwan as the 12th medical advanced among 144 national economies. The country's ability to innovate is also among the four major innovation countries in the world with Germany, the United States and Switzerland. National Development Council is to create a good investment environment. Last year, the Executive Yuan passed the “Optimization of New Investment Action Plan” developed by the National Development Council. Through five major strategies, it created a new early-stage fund to enable the government to integrate angels. Investment, and has invested more than 2 billion Taiwan dollars in 57 new industries, and also became a new venture through talent cultivation, new regulatory frameworks, relaxation of cell therapy technology and telemedicine, and creation of multiple outlets. The team's partners lead them to connect with the international market.



Vice President Chen, Chien-Jen
 
Vice President Chen, Chien-Jen also came to the scene specially. He said that the biomedical industry is a government that has been vigorously promoting the use of the three main axes of connecting the land, connecting the world, and connecting the future. The three main axes are to recruit talents, adjust regulations, and raise funds to improve. The entire industrial ecosystem is committed to building Taiwan into a major city for biomedical research and development in Asia-Pacific. Currently, in Taipei, Hsinchu, Kaohsiung and other regions, special medical biotechnology settlements have been established. Among them, the National Biotechnology Research Park is the most important leader. This event will also link foreign resources and help Taiwan's biomedical innovations to leap to the international arena.
 
Chen, Chien-Jen also pointed out that Taiwan's current biomedical industry has grown by more than 5% in both turnover and investment cases. The combined revenue of listed cabinet companies has reached an annual increase rate of 11%. The market value has also reached 890.4 billion, so in the near future, Taiwan's biotechnology industry is expected to become the next trillion industry.



President of the Academia Sinica James C. Liao

President of the Academia Sinica James C. Liao, said that more than a month ago, the Academia Sinica BioTReC was formally established as a unit of the Academia Sinica in the National Biotechnology Research Park. It will serve the manufacturers together with the Ministry of Health and Welfare, Ministry of Economic Affairs and Ministry of Science and Technology. During the incubation, 11 manufacturers have entered the market, and 12 manufacturers is also signing up. It is expected that a 50% occupancy rate will be reached by the end of this year. In the future, it will actively coach manufacturers to find new companies with innovation, leadership and execution capabilities. And committed to the industry and academic cooperation. In addition, I also invited international companies to enter the country, first signing with AstraZeneca in the UK, and then signing with iPark, Takeda from Japan, and Amgen of the United States, introducing the pharmaceutical experience of international companies to the country. As the National biotechnology research park becomes more mature, it will achieve a clustering effect, making the ecosystem of innovative research more and more complete.


Vice President Chen, Chien-Jen and Taipei Medical University Chairman Chang, Wen-chang


8 enlisted Startup team


In order to allow the participating teams to obtain more professional evaluation suggestions, Pitch Day invited AstraZeneca, global senior vice president and director of the Asian Department of Medicine and the head of the Taipei Medical University. The director of the Big Data Technology and Management Institute, the director of the Shuanghe Hospital, the CEO of the Biotechnology Development Center of the Foundation, and the co-founder of ixensor, etc., as judges panel, The three major scoring criteria were practical feasibility, proposal integrity and innovation. In the final there are 8 selected teams: AESOPTechnology, ATP BioPharm, CancerfreeBiotechLtd, Guzip Biomarkers Corp, cytena Bioprocess Solutions Co., Ltd., TMU KHC team, NHRI-New Co (ABT), Academia Sinica - Amnion Biosciences.
 
Among the 8 selected winners, 4 groups were the from Taipei Medical University, AESOPTechnology, ATP BioPharm, Guzip Biomarkers Corp, TMU KHC team, respectively, in AI drug safety applications, small molecule new drug development, endometrial cancer test reagent development and cancer. The field of dual-function antibody development has been unanimously affirmed.



2019 NBRP Biomed Startup Challenge

本網站使用您的Cookie於優化網站及您的瀏覽經驗。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。